[A21-141] Nivolumab (malignant pleural mesothelioma) - Addendum to Commission A21-89
Last updated 16.12.2021
Project no.:
A21-141
Commission:
Commission awarded on 09.11.2021 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
First-line treatment of unresectable malignant pleural mesothelioma in adults
Result of dossier assessment:
Unchanged after addendum:
- Patients with epithelioid tumour histology: added benefit not proven.
- Patients with non-epithelioid tumour histology: indication of considerable added benefit.
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A21-89 | Nivolumab (malignant pleural mesothelioma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2021-12-16 A G-BA decision was published.